title: Activity of ceftaroline against serotyped Streptococcus pneumoniae isolates from Europe and South Africa associated with community-acquired bacterial pneumonia (2007-08).
abstract: OBJECTIVE
  To determine the activity of ceftaroline (the active metabolite of the prodrug ceftaroline fosamil), a new cephalosporin recently approved in the USA for the treatment of community-acquired bacterial pneumonia, against serotyped Streptococcus pneumoniae causing community-acquired bacterial pneumonia from Europe and South Africa.
  
  
  METHODS
  During 2007-08, 74 centres submitted 857 isolates of S. pneumoniae from patients with community-acquired bacterial pneumonia. These were re-identified and serotyped. MICs of ceftaroline and 12 comparators were determined by CLSI broth microdilution at a central laboratory.
  
  
  RESULTS
  Ceftaroline was very active against all 857 S. pneumoniae isolates (MIC(90) 0.12 mg/L). The MIC(50) for South African isolates was 0.06 mg/L compared with 0.004 or 0.008 mg/L for isolates from elsewhere. Antibiotic resistance was also higher in South Africa than other countries. Serotypes 3, 1, 7 and 11 were more susceptible to ceftaroline (MIC(90) = 0.008 mg/L) and the reference antibiotics than the population as a whole. Ceftaroline showed a biphasic MIC distribution (associated with cefuroxime susceptibility), the extent of which differed between isolate populations. Nevertheless, the highest ceftaroline MIC observed was only 0.5 mg/L (two isolates: one from the UK and one from South Africa).
  
  
  CONCLUSIONS
  These data from a large collection of S. pneumoniae isolates during 2007-08 from Europe and South Africa with varying serotype and antibiotic susceptibility, confirm the excellent in vitro activity of ceftaroline against S. pneumoniae causing community-acquired bacterial pneumonia in both adults and children.
authors.affiliation: Quotient Bioresearch Ltd, Fordham, UK. ian.morrissey@quotientbioresearch.com
authors.forename: Ian
authors.initials: I
authors.lastname: Morrissey
authors.forename: Anne
authors.initials: A
authors.lastname: Leakey
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology*; D002648:Child; D002675:Child, Preschool; D017714:Community-Acquired Infections / Q000382:microbiology*; D005060:Europe; D005260:Female; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D011018:Pneumonia, Pneumococcal / Q000382:microbiology*; D012703:Serotyping; D013019:South Africa; D013296:Streptococcus pneumoniae / Q000145:classification / Q000302:isolation & purification*; D055815:Young Adult; D000097583:Ceftaroline
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000097583:Ceftaroline